Loading clinical trials...

Clinical Safety and Efficacy of Fecal Microbiota Transplantation (FMT) in the Treatment of Alzheimer's Disease | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGNA

Clinical Safety and Efficacy of Fecal Microbiota Transplantation (FMT) in the Treatment of Alzheimer's Disease

Clinical Safety and Efficacy of FMT in the Treatment of Alzheimer's Disease

NCT06920212•Shanghai 10th People's Hospital

View on ClinicalTrials.gov

Summary

To investigate the clinical safety and efficacy of FMT in AD patients, as well as the changes in the gut microbiota of AD patients before and after FMT.

Eligibility

Age

50 - 85 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•The patients (aged 50-85 years) exhibited cognitive decline persisting for over six months;
•Primarily characterized by recent memory impairment and accompanied by reduced daily living abilities;
•MMSE scores ranging from 3 to 26;
•MRI findings revealed atrophy in the medial temporal lobe, hippocampus, and cerebral cortex, along with widened sulci and fissures.

Exclusion Criteria

•Patients were excluded if they had severe visual, hearing, or language impairments;
•Tumors;
•hepatic/renal dysfunction.
•with conditions mimicking AD symptoms-such as normal pressure hydrocephalus, vascular dementia (VD or VaD);
•Parkinson's disease dementia (PDD)-were also excluded;
•patients who had participated in clinical drug trials within the past 30 days or consumed folate and vitamin B12 at doses exceeding twice the recommended intake were ineligible.

Locations (1)

Le Wang

Shanghai, China

Key Dates

Start Date

October 1, 2024

Primary Completion Date

October 31, 2025

Completion Date

December 31, 2025

Last Updated

April 9, 2025

Enrollment

ESTIMATED participants

Conditions

Fecal Microbiota Transplantation

Interventions

FMT capsule

PROCEDURE

Fecal Microbial Transplantation for Rheumatoid Arthritis Trial

NCT05790356

ArthritisArthritis, Rheumatoid+1 more

View study

RECRUITINGPHASE2/PHASE3

Standardized Fecal Microbiota Transplantation for Ulcerative Colitis

NCT01790061

BacteriaMicrobiota+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 9, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Clinical Safety and Efficacy of Fecal Microbiota Transplantation (FMT) in the Treatment of Alzheimer's Disease

Inclusion Criteria

Exclusion Criteria

Fecal Microbial Transplantation for Rheumatoid Arthritis Trial

Standardized Fecal Microbiota Transplantation for Ulcerative Colitis

Long-term Efficacy and Safety of Fecal Microbiota Transplantation in Patients With Ulcerative Colitis

Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer

A Controlled Study on Regulation of Systemic Inflammation by Fecal Bacteria Transplantation in Patients With COVID-19.

Clinical Response and Safety Following FMT for UC